KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis.

Sarah G Bridgeman, Anna K Martino, Lindsay C Strowd

Expert Opin Pharmacother 24(18) 2153-2159

PMID38018382
PMCID-
DOI10.1080/14656566.2023.2288698
发表日期2023-11-29
摘要

摘要

INTRODUCTION: New biologic and small molecule therapeutics have emerged for the treatment of moderate-to-severe atopic dermatitis (AD), including oral Janus kinase (JAK) inhibitors such as baricitinib. While JAK inhibitors are commonly used to treat rheumatoid arthritis and inflammatory bowel disease, these agents are relatively new in the field of dermatology. AREAS COVERED: In this review, we outline the efficacy and safety data of phase III randomized controlled trials investigating the use of baricitinib for moderate-to-severe AD. A literature search was performed using PubMed.gov to identify articles relevant to the topic published before August 2023. EXPERT OPINION: Oral JAK inhibitors in AD management are highly efficacious, whether used alone, in conjunction with topical corticosteroids, or in patients who have failed other conventional systemic medications for AD. JAK inhibitors appear to be well tolerated in the AD patient population with fewer major safety risks than what has been seen in other patient populations. Assessing patient risk factors for cardiovascular, thromboembolic, and oncologic diseases is now an important part of the office visit for patients in whom you may consider using a JAK inhibitor.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。